Medtech company wants to help hospitals open radiation-free interventional MR labs
Imricor Medical Systems, a medtech company known for its MR-compatible EP lab catheter ablation technologies, has launched a vertical to help hospitals establish radiation-free cardiac cath labs. The new entity is officially known as Imricor Cardiovascular.
Minneapolis-based Imricor has already made quite a splash in 2026, securing U.S. Food and Drug Administration (FDA) clearances for its NorthStar Mapping System and Vision-MR Diagnostic Catheter and then receiving additional FDA approvals to use those devices when treating pediatric patients. With Imricor Cardiovascular, the company hopes to help support a new care model that replaces separate MR imaging and X-ray cath lab sessions with a single session held in state-of-the-art interventional MR lab.
Potential benefits of this new approach include significant time savings, freeing up cath lab space for other interventional procedures and reducing patient exposure to ionizing radiation. In addition, according to Imricor, this represents a more efficient use of hospital resources.
“With Imricor Cardiovascular, hospitals can pioneer radiation-free cardiac care, safeguard vulnerable patients and arm care teams with MR imaging,” Greg Englehardt, Imricor’s vice president of global sales, said in a statement. “By doing this they can also put their programs at the leading edge of interventional MR-guided catheterization in the United States.”
“This launch marks an important step forward for both patients and hospitals,” added Imricor CEO Steve Wedan. “We believe better imaging has the power to change how cardiac procedures are performed, and it is especially meaningful to see this change begin with children who can benefit from fewer separate sessions and the elimination of radiation.”
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.